Cellectis Schedule for Q2 2025 Earnings and Key Updates

Cellectis Plans Q2 2025 Financial Results Release

In recent announcements, Cellectis, a pioneering clinical-stage biotechnology firm known for its innovative gene-editing platform, has shared its plans to report financial results for the second quarter of 2025. The report, covering the period ending June 30, is scheduled for release on August 4, 2025, soon after the closing of the U.S. financial markets. This exciting news reflects Cellectis' commitment to providing timely updates to its stakeholders.

Details of Upcoming Investor Call

Following the financial report, Cellectis will host an investor conference call scheduled for August 5, 2025, at 8:00 AM ET. This call aims to provide investors and analysts with insights into the company’s quarterly results and share updates on ongoing business activities. With the rapidly evolving landscape of biotechnology, this call is particularly significant for stakeholders interested in Cellectis’ advancements.

How to Join the Investor Call

Investors can participate in this important call by dialing in using the following numbers. Domestic participants can reach out at +1-800-343-5172, while international participants can connect using +1-203-518-9856.

For ease of access, a specific conference ID, CLLSQ2, will be required for joining the call. This structured approach ensures smooth communication during the event.

About Cellectis and Its Mission

Cellectis stands out in the biotechnology realm by leveraging its advanced gene-editing platform to develop crucial cell and gene therapies. The company has adopted an allogeneic method for CAR T therapies in oncology, revolutionizing treatment options for cancer patients. By offering off-the-shelf gene-edited CAR T-cells, Cellectis is at the forefront of changing how cancer is treated.

One of the company's distinguishing features is its in-house manufacturing capabilities, allowing it to handle the entire value chain of cell and gene therapy development. This end-to-end control positions Cellectis uniquely in the competitive landscape of gene editing and therapy development.

Company Locations and Market Presence

Cellectis has its headquarters in Paris, France, and operates additional locations in New York and Raleigh, NC. The company’s presence in two major markets enhances its position for growth and development in the field of biotechnology. Cellectis is publicly traded on both the Nasdaq Global Market under the ticker CLLS and on Euronext Growth with the ticker ALCLS.

Connecting with Cellectis

For those seeking more information about Cellectis’ initiatives, their official website offers extensive resources. Interested parties can also follow the company on professional networks like LinkedIn or updates on social media platforms to stay informed about their progress and announcements.

Contact Information for Further Queries

For media inquiries, the dedicated contacts at Cellectis include Pascalyne Wilson, Director of Communications, who can be reached at +33 (0)7 76 99 14 33. For investor relations, Arthur Stril, the Chief Financial Officer & Chief Business Officer, is available, further emphasizing the company's openness to engaging with its stakeholders regarding business-related queries.

Frequently Asked Questions

When will Cellectis announce its Q2 2025 financial results?

Cellectis will announce its financial results for the second quarter of 2025 on August 4, 2025.

What time is the investor call scheduled?

The investor conference call will take place on August 5, 2025, at 8:00 AM ET.

How can I join the investor call?

To join the call, dial +1-800-343-5172 for domestic calls or +1-203-518-9856 for international calls, using the conference ID CLLSQ2.

What is the focus of Cellectis as a biotechnology company?

Cellectis focuses on developing life-saving cell and gene therapies through its gene-editing platform.

Where is Cellectis headquartered?

The company’s headquarters is located in Paris, France, with facilities in New York and Raleigh, NC.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.